Combining the Specific Anti-MUC1 Antibody TAB004 and Lip-MSA-IL-2 Limits Pancreatic Cancer Progression in Immune Competent Murine Models of Pancreatic Ductal Adenocarcinoma

Combining the Specific Anti-MUC1 Antibody TAB004 and Lip-MSA-IL-2 Limits Pancreatic Cancer Progression in Immune Competent Murine Models of Pancreatic Ductal Adenocarcinoma

Immunotherapy regimens have shown success in subsets of cancer patients; however, their efficacy against pancreatic ductal adenocarcinoma (PDA) remain unclear. Previously, we demonstrated the potential of TAB004, a monoclonal antibody targeting the unique tumor-associated form of MUC1 (tMUC1) in the...

Full description

Bibliographic Details
Main Authors: Didier Dréau, Laura Jeffords Moore, Mike Wu, Lopa Das Roy, Lloye Dillion, Travis Porter, Rahul Puri, Noor Momin, K. Dane Wittrup, Pinku Mukherjee
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-04-01
Series:Frontiers in Oncology
Subjects:
ADCC
Antibody
IL-2
Immunocompetent
Immunotherapy
MUC1
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00330/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.00330/full

Similar Items